Publications by authors named "F M F Rosier-van Dunne"
The cardio-metabolic protein profile is associated with development of type 2 diabetes at long term follow-up after gestational diabetes mellitus: Results from the OGFUS study.
Diabetes Obes Metab
January 2025
Aims: Women with previous gestational diabetes mellitus (GDM) have an increased risk for later development of type 2 diabetes. During pregnancy, GDM affects the cardio-metabolic protein profile; however, it is unknown how GDM affects the cardio-metabolic protein profile in the long term and if it is associated with type 2 diabetes after GDM. We hypothesise that the cardio-metabolic protein profile is affected long term and is associated with the development of type 2 diabetes after GDM.
View Article and Find Full Text PDFArticle Synopsis
- Clinical trials, essential for healthcare, also significantly contribute to climate change; researchers have developed a method to calculate their carbon footprint and applied it to 10 UK and international trials.
- Data on trial activities was collected from 10 trial units, evaluated for emission sources, and feedback was gathered on the carbon footprint calculation process.
- The carbon footprints of the trials varied widely, highlighting key areas for emissions reduction, with suggestions to incorporate carbon footprint considerations during the trial design phase.
Aims/hypothesis: Gestational diabetes mellitus (GDM) is associated with adverse perinatal outcomes because of suboptimal glucose management and glucose control and excessive weight gain. Metformin can offset these factors but is associated with small for gestational age (SGA) infants. We sought to identify risk factors for SGA infants, including the effect of metformin exposure on SGA status.
View Article and Find Full Text PDFMetformin is a commonly used drug in the treatment of type 2 diabetes and has been used to treat gestational diabetes since the 1970s. In pregnancy, its proven benefits include reduced gestational weight gain and reduced fetal size; some studies have shown reduced risk of cesarean delivery and lower rates of hypertension. Metformin can reduce the need for insulin therapy but does not eliminate such need in many patients.
View Article and Find Full Text PDFAims: To undertake a Priority Setting Partnership (PSP), identifying the most important unanswered questions in type 1 diabetes in Ireland and the United Kingdom and to compare these to priorities identified in a 2011 PSP.
Methods: A steering committee (including eight individuals with lived experience/charity representatives and six clinicians) designed a survey which asked stakeholders to list three questions about type 1 diabetes. This was disseminated through social media, direct email contact, and printed posters.